Eyewire News: The Podcast
Outlook Therapeutics takes a major step forward in its plan to gain approval for wet AMD drug Lytenava; the first commercial FLIGHT procedures using the ViaLuxe Laser System are performed in Europe; and Oculus introduces a new AI-assisted tool designed to help clinicians evaluate MGD using meibography images. Learn more about your ad choices. Visit megaphone.fm/adchoices [https://megaphone.fm/adchoices]
101 episodios
Comentarios
0Sé la primera persona en comentar
¡Regístrate ahora y únete a la comunidad de Eyewire News: The Podcast!